Role of interferon lambda 4 and ALT levels in optimising treatment of HCV for patients with low-stage fibrosis by Figorilli, Francesco et al.
ABSTRACT: 
— The use of new anti-HCV drugs is currently limited by high costs and dual therapy; pegylated interferon
and ribavirin (peg-IFN+RBV) still represents the only affordable treatment in patients with low-stage fibrosis.
We evaluated the role of Interferon lambda4 (IFNL4) polymorphisms and its combination with on-treatment
alanine transaminase (ALT) modification in predicting sustained virological response (SVR) in HCV genotype
1 and 4 patients with low-stage fibrosis. We retrospectively analysed 124 patients with Metavir ≤F2, who
received dual therapy at our centre. Genotyping for IFNL4 polymorphisms was assessed at baseline, as well
as ALT levels (baseline and week 2, 4, 12 and 24 of therapy). Thirty patients (24%) were TT/TT, 74 (60%)
TT/DG and 20 (16%) DG/DG. The SVR rate was significantly higher in TT/TT genotype compare to TT/DG
and DG/DG (97% vs. 53% and 50%, respectively, p=0.001). Patients that achieved a 60% reduction of
ALT baseline value after 4 weeks of therapy had a significantly higher SVR rate (94% vs. 52%, p<0.001).
Factors significantly associated with SVR were TT/TT genotype (p=0.029), RVR (p=0.019) and 60% ALT re-
duction at 4 week of therapy (p=0.005). The absence of both TT/TT genotype and 60% ALT reduction
were negative predictors of SVR (p<0.001). In conclusion, the combined use of IFNL4 polymorphisms and
ALT reduction at 4 week of treatment is able to optimize candidates’ selection for peg-IFN+RBV, discrimi-
nating those that could still benefit from dual therapy from the ones that need the new regimens.
— Keywords: Chronic hepatitis C, Sustained virological response, Pegylated interferon, Ribavirin.
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ABBREVIATIONS
HCV: Hepatitis C virus; peg-IFN+RBV: pegylated in-
terferon and ribavirin; SVR: sustained virological re-
sponse; DAAs: direct antiviral agents; EVR: early
virological response; IFNL: interferon lambda; DG:
delta-G; ALT: alanine transaminase; RVR: rapid viro-
logical response; NR: non responders; REL: relapsers;
ISG: interferon-stimulated genes.
INTRODUCTION 
Hepatitis C virus (HCV) infection is a major global
health issue with more than 170 millions infected people
worldwide1. Genotype 1 and 4 account for the majority
of chronic HCV infections particularly in the Middle
East, North Africa and sub-Saharan Africa2. Until 2011,
the dual therapy based on pegylated interferon and rib-
avirin (peg-IFN+RBV) for 48 weeks was the only ap-
proved treatment for genotype 1 and 43, with a sustained
virological response (SVR) rate of approximately 50%.
The advent of the new direct antiviral agents (DAAs) has
radically changed the prognosis of patients with HCV,
achieving a SVR rate greater than 90%. For this reason,
in current guidelines dual therapy with peg-IFN+RBV
has been replaced by new regimens that contain usually
one DAA. The recommended regimen to treat naive pa-
tients with HCV genotype 1 and 4 and low-stage fibrosis
is Sofosbuvir+peg-IFN+RBV for 12 weeks4. Unfortu-
nately, for most of the countries, especially the develop-
ing ones, the new guidelines are economically
unsustainable due to the high costs of the new drugs. In
this setting, DAAs availability has been limited to pa-
tients with advanced liver disease5 and peg-IFN+RBV is
still the only treatment option for most of the patients.
Several predictive factors of SVR have been identified
in the last decade, such as early virological response
(EVR)6. Genome-wide association studies have identified
a single nucleotide polymorphism on chromosome 19q13
near the interferon lambda 3 gene (formerly known as
IL28B) as variants positively associated with the re-
sponse to peg-IFN+RBV treatment7,8. More recently, a
dinucleotide polymorphism (ss469415590) that creates
or disrupts an open reading frame in a recently discov-
ered gene, interferon lambda 4(IFNL4), has been showed
to be strongly involved in response to antiviral therapy9,10.
The IFNL4 gene (encoding IFNL4) is situated upstream
of interferon lambda 3. The one-base deletion in the
delta-G (DG) variant results in a frame shift, which in
turn produces the full-length protein designated as
IFNL4; the TT variant does not produce IFNL411. The
TT/TT variant seems to be associated with impaired
clearance of HCV infection and response to peg-IFN
therapy12. In this study we explored the role of IFNL4
polymorphisms and on-treatment change of viral load
and alanine transaminase (ALT) in predicting the re-
sponse to peg-IFN+RBV therapy in a cohort of patients
affected by chronic HCV genotype 1-4 infection and low-
stage fibrosis. 
PATIENTS AND METHODS
In this retrospective study we included patients with
chronic HCV infection who underwent antiviral therapy
with peg-IFN alpha-2a and RBV at the Liver Unit of Uni-
versity of Cagliari between January 2003 and January
2012. All of them were infected by HCV genotype 1 or 4
and had a liver fibrosis stage lower than F3, as assessed
by Metavir score. Chronic hepatitis C was defined as the
presence of HCV RNA and abnormal ALT levels for more
than six months. Clinical and laboratory data were col-
lected at baseline and at week 2, 4, 12 and 24 of therapy.
A percutaneous liver biopsy was performed before start-
ing the antiviral therapy and liver fibrosis stage was as-
sessed by Metavir score system. Polymorphisms from
ss469415590 (IFNL4) and rs12979860 (IL28B) were
analysed as follows: genomic DNA was isolated from 200
μl of serum samples with the QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany) to test. SNPs for
IFNL4were analysed in 7500 Fast Real Time PCR System
(Applied Biosystems, Foster City, USA) using an Assay
On-demand and two Custom TaqMan SNP Genotyping
Assays, respectively. HCV genotype was detected by Ver-
sant HCV genotype 2.0 Assay (LIpa-Siemens, Erlangen,
Germany). HCV RNA was quantified by COBAS AM-
PLICOR/HCV Monitor (Roche, Mannheim, Germany)
and real-time PCR assay (COBAS AmpliPrep/COBAS
TaqMan 48-Roche). On treatment virological response
was defined as rapid virological response (RVR) when
HCV RNA was undetectable at week 4. Early virological
response (EVR) was defined as the occurrence of negative
HCV RNA (complete EVR) or reduction >2 logs of HCV
RNA (partial EVR) after 12 weeks of treatment. SVR was
defined as undetectable serum HCV RNA 24 weeks after
the discontinuation of therapy. Patients were considered
non-responders (NR) if HCV RNA remained positive dur-
ing therapy and relapsers (REL) when there was A re-
bound in HCV RNA 24 weeks after the end of treatment.
Continuous parametric variables were expressed as mean
± standard deviation (SD) and were compared using
ANOVA or Student-t tests, as appropriate. Non-paramet-
ric variables were presented as median and range, and
compared by Kruskal-Wallis Test. Categorical variables
were compared using the chi-squared test. The percentage
of ALT decrease during treatment was obtained by the fol-
lowing formula: ((Day0 level minus two-week
level)/Day0 level). ROC analysis was used to assess the
best cut-off of the decrease of ALT at week 2 and 4 of
therapy. Logistic regression analysis was used to identify
the predictors of SVR. We tested in the univariate analysis
parameters at baseline, week 2 and week 4 of therapy and
the variables with a p<0.05 were included in the multi-
variate logistic regression. SPSS software package (ver-
sion 20.0, SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. Local ethic committee approved the
study.
RESULTS
Baseline characteristics
One hundred twenty-four outpatients followed between
January 2003 and January 2012 at the Liver Unit of Uni-
versity of Cagliari were included in the study. Eighty-one
(65.3%) were infected by HCV genotype 1 and 43
(34.7%) by genotype 4. The mean age was 43.4 years
(SD 10.3) and 89 (71.8%) were males. All patients re-
ceived antiviral treatment based with peg-IFN+RBV for
a median period of 47 weeks. In the 24-week follow-up
after therapy, 78 patients (62.9%) achieved SVR, 21 pa-
tients (16.9 %) were REL and 25 (20.2%) were NR.
IFNL4Genotyping
The main characteristics of the patients stratified accord-
ing the ss469415590 polymorphism (TT/TT, TT/DG,
DG/DG) are shown in Table 1. Seventy-four (59.7%) pa-
tients were TT/DG, 30 (24.2%) TT/DG and 20 (16.1%)
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DG/DG. At baseline, only gamma-glutamyl transpepti-
dase level was significantly lower in TT/TT patients
(TT/TT 25.5 IU/L, TT/DG 60 IU/L, DG/DG 53.5IU/L,
p<0.001). RVR, EVR and SVR rate were significantly
higher in TT/TT patients. The SVR rate in TT/TT was
96.7% compared to 52.7% in DG/TT and 50% in DG/DG
(p<0.001).
ALT variation
The percentage of ALT decrease during therapy was dif-
ferent between the three genotypes of IFNL4. As showed
in Figure 1a, after 2 weeks of treatment TT/TT patients
had a median ALT decrease of 35.5%, which was signif-
icantly higher compared to genotypes TT/DG and
DG/DG (13.7% and 8.4% respectively, p=0.002). After
4 weeks, the difference was lower but still significant
(p=0.006) and at 12 weeks the reduction was similar be-
tween the three genotypes (p=0.082). The median rate of
decrease was significantly higher in SVR group com-
pared to REL and NR after 2 weeks (24.6% vs. 4.7%;
p=0.001), after 4 weeks (44.6% vs. 23.5%; p=0.001),
after 12 weeks (59.6% vs. 45.5%; p=0.004) and after 24
weeks (66.8% vs. 41.8%; p=0.002) (Figure 1b). The best
cut-off obtained by ROC analysis was 20% at 2 weeks
of therapy (AUC 0.679, sensitivity 60.3%, specificity
76.1%; p<0.001) and 60% at 4 weeks (AUC 0.687, sen-
sitivity 38.5%, specificity 95.7%, p<0.001). As reported
in Table 2, a decrease of ALT baseline level greater than
20% after 2 weeks of treatment was significantly associ-
ated with a higher rate of SVR (60.3% vs. 39.7%;
p<0.001). Moreover patients that achieved a 60% reduc-
tion at week 4 of therapy had an SVR rate of 93.8% vs.
52.2% in patients with a lower decrease (p<0.001). Less
patients with genotype DG/DG had a 60% reduction at
week 4 (10%) compared to the other genotypes (20% in
TT/DG, 50% in TT/TT, p=0.002). However, patients
without favorable genotype, but showing ALT decrease,
still achieved a higher SVR rate compared to those with-
out ALT reduction (88% vs. 44%, p<0.001).
Predictors of response to treatment
In multivariate logistic regression (Table 2), factors sig-
nificantly associated with SVR were TT/TT genotype
(p=0.029, OR=10.74, 95%CI 1.28-89.84), RVR (p=0.019,
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Table 1. General characteristics of the study population, stratified according to IFNL4 genotype.
                                                            Total (n=124)           TT/TT (n=30)             TT/DG (n=74)         DG/DG (n=20)       p-value
Male, n (%)                                          89 (71.8)                  19 (63.3)                     55 (74.3)                  15 (75)                    NS
Age, years, median (range)                  43 (24-69)                42.5 (25-77)               43.5 (24-69)             39 (30-62)               NS
Previous therapy, n.(%)                        28 (37.1)                  5 (16.6)                     18 (24.3)                  5 (25)                    NS
BMI, kg/m2, mean (SD)                      24.8 (2.9)                 24.8 (3.2)                    24.7 (3.2)                 24.7 (3.0)                NS
HCV genotype n. (%)
- 1                                                     81 (65.3)                  21 (70)                        44 (59.5)                  16 (80)                    NS
- 4                                                     43 (34.7)                  9 (30)                        30 (40.5)                  4 (20)                    
IL28B,n. (%)
- CC                                                  30 (24.2)                  30 (100)                      0 (0)                       0 (0)                      <0.001
- CT                                                  74 (59.7)                  0 (0)                          74 (100)                   0 (0)                      
- TT                                                  20 (16.1)                  0 (0)                          0 (0)                       20 (100)                  
Platelets, cell/mm³, mean (SD)            221190                    217333                       216973                    240000                   NS
                                                             (±50924)                  (±44641)                     (±51157)                  (±53808)                 
AST, IU/L, median (range)                  38 (16-230)              45.5 (20-230)             39 (18-105)             36 (16-69)               NS
ALT, IU/L, median (range)                  66 (14-652)              75 (23-652)                63.5 (14-212)          60 (23-104)             NS
GGT, IU/L, median (range)                 43 (9-292)                25.5 (10-114)              60 (9-292)               53.5 (21-137)          <0.001
HCVRNA, IU/ml, median (range)       712000                    651500                       903500                    385500                   NS
                                                             (600-13200000)       (7940- 13200000)      (600- 9550000)       (36900-9080000)
Weeks of therapy,median                     47 (12-71)                47 (24-59)                  47 (18-71)                46.5 (12-50)            0.004
(range)                                                
Decrease of ALT at week 2
(median)                                             -16.6%                      -35.5%                         -13.7%                      -8.4%                       0.003
Decrease of ALT at week 4                  -37.9%                      -58.5%                         -38.1%                      -28.1%                     0.006
(median)
Decrease of ALT at week 12                -53.5%                      -65.4%                         -52%                         -53.6%                     NS
(median)                                             
Decrease of ALT at week 24                -59.3%                      -69.2%                         -55.3%                      -52.8%                     0.038
(median)
RVR, n. (%)                                          -27 (21.8)                  13 (43.3)                     12 (16.2)                  2 (10)                    0.004
EVR, n. (%)                                          76 (61.3)                  27 (90)                        41 (55.4)                  8 (40)                    <0.001
SVR, n. (%)                                          78 (62.9)                  29 (96.7)                     39 (52.7)                  10 (50)                    0.001
Relapse, n. (%)                                     21 (16.9)                  1 (3.3)                       16 (21.6)                  4 (20)                    
Non-responder, n. (%)                          25 (20.2)                  0 (0)                          19 (25.7)                  6 (30)                    
DG: delta-G. BMI: body mass index. AST: aspartate transaminases. ALT: alanine transaminases. GGT: gamma-glutamyl transaminases.
NS: not significant. RVR: rapid virological response. EVR: early virological response. SVR: sustained virological response.
Figure 1. A, Rate of ALT decrease at different time points of treatment according to IFNL4 polymorphisms. B, Rate of ALT decrease at
different time points of treatment according to virological response.
A
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OR=6.68, 95%CI 1.36-32.87) and ALT reduction at week
4 of therapy >60% (p=0.005, OR=9.46, 95%CI 1.99-
45.08). On the other hand, the absence of RVR (p=0.018,
OR 6.751, 95%CI 1.38-33) and the combination of an un-
favorable IFNL4 genotype (TT/DG or DG/DG) with a re-
duction of ALT at week 4 <60% (p<0.001, OR=0.06,
95%CI 0.02-0.23) were negative predictors of SVR. In
particular, only 44.2% of patients showing this combina-
tion achieved a SVR compared to those with the same un-
favorable genotype, but greater ALT decrease (88.2%,
p<0.001) (Figure 2b).
DISCUSSION 
The new anti-HCV drugs are highly effective, being able
to cure more than 90% of treated patients4. However, they
are very expensive and their prescription to all infected
subjects is economically unsustainable for most countries
worldwide. Moreover, their availability is extremely lim-
ited in many low-income countries5. Similarly to anti-
HIV treatment13, the possibility to identify those
individuals that can be cured with the less expensive ther-
apy (peg-IFN+RBV) would be very useful to focus the
financial resources on patients that will require the new
DAAs to achieve a sustained virological response. In this
retrospective analysis we aimed at identifying factors that
could predict the response to peg-IFN+RBV within 4
weeks of therapy. We focused on patients affected by
HCV genotype 1 and 4 and low-stage fibrosis, because
they represent the majority of HCV infected patients in
the developing country2. First, we analysed the role of
IFNL4 genes, a novel transcribed region recently identi-
fied by Prokunina-Olson et al9, and located close to the
three interferon lambda genes: IFNL1 (IL29), IFNL2
(IL28A) and IFNL3 (IL28B). IL28B polymorphisms are
the strongest predictors of response to therapy in HCV
genotype 17,8,14-18. The region of IFNL4 harboured a din-
ucleotide variant (ss469415590) that has been found in
two alternative forms, either DG or TT alleles. The one-
base deletion in the DG variant results in a frameshift,
which in turn produces the full-length protein, called
IFNL4; on the opposite, the TT variant does not produce
IFNL49,11. In our cohort, an important peculiarity was that
IFNL4 and IL28B polymorphisms showed a perfect
match: TT/TT with CC, TT/DG with CT and DG/DG
with TT. Data from literature indicates that the correspon-
dence between IL28B and IFNL4 genotypes is about
92% in the Caucasian ethnicity9, so it is not clear if our
findings represented the real distribution of these alleles
or if they were due to an artefact related to the small sam-
ple size. Therefore, from nowhere we refer only to IFNL4
genotype when commenting the results. It is noteworthy
that all of patients with the TT/TT genotype cleared the
virus after a peg-IFN+RBV course of treatment and only
1 of them relapsed. On the other hand, only half of the
patients with the unfavourable genotype (DG/DG) or het-
erozygosis (TT/DG) achieved SVR. The pathophysiolog-
ical mechanism that links IFNL4 polymorphisms and
HCV clearance after treatment with peg-IFN+RBV has
been investigated in several studies. In vitro, IFNL4 in-
duces the expression of interferon-stimulated genes (ISG)
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4
ROLE OF INTERFERON LAMBDA 4 AND ALT LEVELS IN OPTIMISING TREATMENT OF HCV
5
Table 2. Characteristics of patients stratified by treatment response and univariate and multivariate logistic analyses of predictors 
of sustained virological response (SVR).
                                                    SVR                 REL+NR       Univariate logistic regression     Multivariate logistic regression
                                                     
                                                     78 (62.9%)      46 (37.1%)     OR          95% I.C.      p value    OR           95% I.C.        p value
                                                                                                                     
Male, n. (%)                                 59 (66.3)          30 (33.7)         1.66        0.75-3.66      NS                                                 
Age, years (median)                    43                     42.5                0.99        0.96-1.03      NS                                                 
Previous therapy, n. (%)              17 (60.7)          11 (39.3)         0.89        0.37-2.11       NS                                                 
BMI, kg/m2 (mean)                     24.7                  25.1                0.99        0.84-1.08      NS                                                 
HCV genotypes n. (%)                                                                                                                                                        
1                                                   51 (63)             30 (37)            1.01        0.47-2.17      NS                                                 
4                                                   27 (62.8)          16 (37.2)         0.99        0.46-2.13      NS                                                 
INFL4 genotypes (%)                                                                                                                                                         
TT/TT                                          29 (96.7)          1 (3.3)           26.63        3.48-203.6    0.002       10.74        1.28-89.84      0.029
TT/DG                                         39 (52.7)          35 (47.3)         0.314      0.14-0.71      0.005       0.95          0.31-2.90        NS
DG/DG                                        10 (50)             10 (50)            0.53        0.20-1.39      NS                                                 
Platelets, cells/mm³ (mean)         216413             223346           1.00        1.00-1.00      NS                                                 
AST, IU/L (median)                    39.5                  37.5                1.01        0.99-1.02      NS                                                 
ALT, IU/L (median)                    67                     62                   1.01        1.00-1.02      NS                                                 
GGT, IU/L (median)                    38                     69.5                0.99        0.98-0.99      0.002       0.99          0.98-1.00        NS
HCVRNA, IU/ml (median)         414000             1090000         1.00        1.00-1.00      NS           
Decrease ALT                              47 (79.6)          12 (21.4)         4.30        1.93-9.55      <0.001     2.06          0.77-5.48        NS
after 2 weeks >20%                   
Decrease ALT                              30 (93.8)          2 (6.2)           13.75        3.10-60.93    0.001       9.46          1.99-45.08      0.005
after 4 weeks >60%
Decrease ALT                              24.6%               4.7%             0.99        0.98-1.00      0.040       1.00          0.99-1.02        NS
after 2 weeks (median) 
Decrease ALT                              44.6%               23.5%             0.99          0.98-1.00      NS
after 4 weeks (median)              
RVR (%)                                      25 (92.6)          2 (7.4)           10.38        2.33-46.26    0.002       6.68          1.36-32.87      0.019
REL: relapser. NR: non-responder. IFNL: interferon lambda. DG: delta-G. BMI: body mass index. AST: aspartate transaminases. ALT:
alanine transaminases. GGT: gamma-glutamyl transaminases. RVR: rapid virological response. EVR: early virological response. SVR:
sustained virological response.
Figure 2. A, Percentage of SVR according to the presence of TT/TT IFNL4 genotype, decrease greater than 60% after 4 weeks of treatment
and Rapid Virological Response (RVR). B, Percentage of SVR according to the combination of TT/TT genotype and ALT decrease greater
than 60% after 4 weeks of treatment: presence of both of them (+TT/+DEC), TT/TT genotype without decrease (+TT/-DEC), decrease
>60% at 4 wk in unfavourable IFNL4 genotype (-TT/+DEC) and the absence of both of them (-TT/-DEC).
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in a similar pattern to those induced by peg-IFN alpha
and IL28B (9). A high baseline hepatic ISG expression
correlates with poor response to peg-IFN therapy19,20 and
it is associated with the unfavourable IL28B genotype21.
Similarly, HCV infected patients carrying the un-
favourable IFNL4 genotype DG/DG, and to a lesser ex-
tent ΔG/TT heterozygosis, showed a persistent and
dose-dependent expression of IFNL4 ISG in the hepato-
cytes9. Although moderate ISG expression can partially
impair viral replication, it also stimulates negative regu-
latory pathways that ultimately reduce hepatocellular
sensitivity to exogenous IFN. Therefore the IFN-alpha
administered during therapy might fail to induce an ef-
fective inflammatory response able to eradicate the in-
fection22,23. On the contrary, patients with the favourable
IFNL4 allele TT/TT show lower level of hepatic ISG ex-
pression at baseline9. Although this phenomenon might
result in a higher baseline viral load, hepatocytes can be
more sensitive to IFN stimulation compared to the un-
favourable genotype22,23. We have also studied the poten-
tial role of the baseline level of alanine aminotransferase
(ALT) and the decrease of this enzyme during treatment
as predictors of SVR. Controversial results have been re-
ported regarding the predictive value of ALT level at
baseline24-28, while so far few studies have described ALT
changes during therapy29. In our study, the absolute val-
ues of ALT at baseline and during treatment were not sig-
nificantly associated with SVR. However, when
considering the degree of variation at predefined time
points during treatment, we found that patients achieving
SVR had a higher decrease compare to nonresponders
and relapsers, especially after 2 weeks and 4 weeks of
therapy. A significant difference has also been found
among the IFNL4 genotypes, because TT/TT patients
presented the highest decrease of ALT at each time point
of therapy. Similarly to the differences among the classes
of response, the gap with the non-favourable genotypes
was greater after 2 weeks and 4 weeks. However the
60% cut-off of the decrease at week 4 showed a higher
specificity than the 20% cut-off at 2 weeks of treatment
(95.7% vs. 76.1%). These results were confirmed in the
multivariate analysis, where a decrease greater than 60%
after 4 weeks of therapy was a predictor of SVR together
with TT/TT genotype and RVR. The rate of SVR for
each of these predictors was more than 90%. When we
looked at the negative predictors, we found that patients
without a favourable TT/TT genotype who presented a
decrease of basal ALT less than 60% had a risk of treat-
ment failure 13 times higher. In fact, the combination of
TT/TT with the 60% decrease at week 4 had a signifi-
cantly higher rate of SVR when compared to the con-
temporary absence of both of them. Based on these
findings, we propose a stopping rule for patients carrying
the unfavourable IFNL4 genotype (TT/DG or DG/DG)
according to the presence of the 60% decrease of ALT
after 4 weeks of therapy and/or a RVR (Figure 3). Pa-
tients who present one of these features have high
chance to achieve SVR and should complete a 48-week
course with peg-IFN and RBV. 
CONCLUSIONS
We suggest that dual therapy could still be an effective
treatment in selected subsets of patients with HCV geno-
type 1 or 4 infection and low-stage fibrosis. Genotyping
of IFNL4 polymorphisms and the variation of ALT serum
level and viral load during treatment represent affordable
tools to identify ideal candidates for peg-IFN+RBV ther-
apy. The use of our algorithm may help to reduce the
number of HCV-infected patients requiring the new
DAAs and therefore contribute to optimize the health-
care-related costs.
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